A5102956125- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Retinoids in leukemia and cellular processes
- Immunotherapy and Immune Responses
- interferon and immune responses
- Immune Cell Function and Interaction
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Virus-based gene therapy research
- Multiple Myeloma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Glycosylation and Glycoproteins Research
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- RNA Interference and Gene Delivery
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Stroke Rehabilitation and Recovery
- Advanced biosensing and bioanalysis techniques
- Biosimilars and Bioanalytical Methods
- Chemokine receptors and signaling
- Acute Ischemic Stroke Management
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- Renal and related cancers
Gerresheimer (Germany)
2024
Heidelberg University
2013-2023
University Hospital Heidelberg
2016-2023
Rhön-Klinikum
2021
Universität Ulm
2010-2020
Helmholtz-Institute Ulm
2020
University Hospital Ulm
2010-2016
Klinikum rechts der Isar
2009
Background Recently, we demonstrated immunological and clinical responses to a RHAMM-R3 peptide vaccine in patients with acute myeloid leukemia, myelodysplastic syndrome multiple myeloma. To improve the outcome of vaccine, second cohort was vaccinated higher dose 1,000 μg peptide.Design Methods Nine received four vaccinations subcutaneously at biweekly interval. Immunomonitoring cytotoxic CD8+ as well regulatory CD4+ T cells performed by flow cytometry enzyme-linked immunospot (ELISpot)...
Introduction Therapy with chimeric antigen receptor T (CART) cells for hematological malignancies has shown promising results. Effectiveness of CART may depend on the ratio naive (TN) vs. effector (TE) cells, TN being responsible an enduring anti-tumor activity through maturation. Therefore, we investigated factors influencing TN/TE cells. Materials and Methods were generated upon transduction PBMCs a CD19.CAR-CD28-CD137zeta 3rd generation retroviral vector under two different stimulating...
Chimeric antigen receptor (CAR) T cells are considered genetically modified organisms (GMOs) and constitute gene therapy medicinal products. Thus, CAR cell manufacturing for clinical application is strictly regulated. Appropriate methods to assess vector copy numbers (VCNs) in products monitoring of frequencies patients required. Quantitative polymerase chain reaction (qPCR) the preferred method VCN assessment. However, no standardized procedure with high reproducibility has been described...
Chimeric antigen receptor (CAR) T cells spark hope for patients with CD19+ B cell neoplasia, including relapsed or refractory (r/r) acute lymphoblastic leukaemia (ALL) r/r non-Hodgkin's lymphoma (NHL). Published studies have mostly used second-generation CARs 4-1BB CD28 as costimulatory domains. Preclinical results of third-generation incorporating both elements shown superiority concerning longevity and proliferation. The University Hospital Heidelberg is the first institution to run an...
In acute myeloid leukemia (AML) without retinoic acid receptor (RAR) rearrangement, the effect of all-trans-retinoic (ATRA) is still poorly understood despite an association NPM1 mutation and ATRA response. Recently, preferentially expressed antigen in melanoma (PRAME) has been shown to be a dominant repressor RAR signaling.Thus, we further investigated response mechanisms, especially impact PRAME expression on responsiveness. We profiled gene diagnostic samples derived from our AML HD98B...
Novel therapies with chimeric antigen receptor (CAR)-transduced T cells (TCs) sparked new hope for patients relapsed or refractory CD19-positive leukemia lymphoma even after stem cell therapies. This review focuses on CARs recognizing the B CD19. Both retroviral and lentiviral vectors are used, encoding various anti-CD19 CAR constructs comprising costimulatory molecules such as CD28, CD137/4-1BB, OX40 either alone (second-generation CARs) in combination (third-generation CARs). Current,...
Leukemic stem cells (LSC) might be the source for leukemic disease self‐renewal and account relapse after treatment, which makes them a critical target further therapeutic options. We investigated role of cytotoxic T‐lymphocytes (CTL) counteracting recognizing LSC. Leukemia‐associated antigens (LAA) represent immunogenic structures to enriched LSC‐containing fraction 20 AML patients hematopoietic (HSC) healthy volunteers. Using microarray analysis qRT‐PCR we detected high expression several...
Summary Nucleophosmin1 (NPM1) is one of the most commonly mutated genes in AML and often associated with a favourable prognosis. Immune responses play an increasing role treatment decisions; however, immune checkpoint inhibition still not clear. To address this, we investigated specific against NPM1, three other leukaemia‐associated antigens (LAA), PRAME, Wilms' tumour 1 RHAMM patients. We T cell leukaemic progenitor/stem cells (LPC/LSC) using colony‐forming immunoassays flow cytometry....
Immune checkpoint inhibitors can block inhibitory molecules on the surface of T cells, switching them from an exhausted to active state. One these immune checkpoints, programmed cell death protein 1 (PD-1) is expressed subpopulations in acute myeloid leukemia (AML). PD-1 expression has been shown increase with AML progression following allo-haematopoeitic stem transplantation, and therapy hypomethylating agents. We have previously that anti-PD-1 enhance response leukemia-associated antigen...
This article explores the meanings of infrastructural changes resulting from Corredor Interoceánico del Istmo de Tehuantepec (CIIT) infrastructure project for cultural survival Indigenous peoples resident in Isthmus region through lens ontological justice. Based on interviews with affected residents states Oaxaca and Veracruz, this research finds a strong desire continuity, collective life projects, languages, identities, beliefs, spirituality, established political legal systems, solidarity...
T cell responses against malignant cells play a major role in maintaining remission and prolonging overall survival patients after allogeneic stem transplantation donor lymphocyte infusion (DLI) due to graft-versus-leukemia effect. For better characterization of the responses, we assessed frequency diversity leukemia-associated antigen (LAA)-specific cytotoxic using ELISpot pMHC multimer assays analyzed regulatory (Treg) as well cytokine profiles before/after DLI. The data were correlated...
Door-to-CT scan time (DCT) and door-to-needle (DNT) are important process measures in acute ischemic stroke (AIS) patients undergoing intravenous thrombolysis (IVT). We examined the impact of a telemedical prenotification by emergency medical service (EMS) (called "Stroke Angel" program) on DCT DNT IVT rate compared to standard care.Two prospective observational studies including AIS admitted via EMS from 2011 2013 (cohort I; n = 496) January 1, 2015 May 31, 2018 II; 349) were conducted....
Rationale: Patients receiving an allogeneic stem cell graft from cytomegalovirus (CMV) seronegative donors are particularly prone to CMV reactivation with a high risk of disease and mortality.Therefore we developed manufactured novel vaccine initiated clinical phase I trial phosphoprotein 65 (CMVpp65)-derived peptide.Methods: Ten patients after transplantation received four vaccinations at biweekly interval.All were monitored for CMVpp65 antigenemia.Flow cytometry CMV-specific CD8 + γδ T...